Research Progress of MicroRNA in Early Detection of Ovarian Cancer

被引:26
作者
Wang, Ze-Hua [1 ,2 ]
Xu, Cong-Jian [1 ,2 ]
机构
[1] Fudan Univ, Obstet & Gynecol Hosp, Shanghai 200011, Peoples R China
[2] Shanghai Key Lab Female Reprod Endocrine Related, Shanghai 200011, Peoples R China
关键词
Detection Method; MicroRNA; Ovarian Cancer; SENSITIVE DETECTION; PROGNOSTIC MARKER; CHAIN-REACTION; TUMOR-MARKERS; SERUM; BIOMARKERS; EXPRESSION; CHEMORESISTANCE; QUANTIFICATION; PROLIFERATION;
D O I
10.4103/0366-6999.171459
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: This review aimed to update the progress of microRNA(miRNA) in early detection of ovarian cancer. We discussed the current clinical diagnosis methods and biomarkers of ovarian cancer, especially the methods of miRNA in early detection of ovarian cancer. Data Sources: We collected all relevant studies about miRNA and ovarian cancer in PubMed and CNKI from 1995 to 2015. Study Selection: We included all relevant studies concerning miRNA in early detection of ovarian cancer, and excluded the duplicated articles. Results: miRNAs play a key role in various biological processes of ovarian cancer, such as development, proliferation, differentiation, apoptosis and metastasis, and these phenomena appear in the early-stage. Therefore, miRNA can be used as a new biomarker for early diagnosis of ovarian cancer, intervention on miRNA expression of known target genes, and potential target genes can achieve the effect of early prevention. With the development of nanoscience and technology, analysis methods of miRNA are also quickly developed, which may provide better characterization of early detection of ovarian cancer. Conclusions: In the near future, miRNA therapy could be a powerful tool for ovarian cancer prevention and treatment, and combining with the new analysis technology and new nanomaterials, point-of-care tests for miRNA with high throughput, high sensitivity, and strong specificity are developed to achieve the application of diagnostic kits in screening of early ovarian cancer.
引用
收藏
页码:3363 / 3370
页数:8
相关论文
共 62 条
[1]  
[Anonymous], PRACT J CANC
[2]  
[Anonymous], INT J GYNECOL OBESTE
[3]  
[Anonymous], MOL CARCINOG
[4]  
[Anonymous], J MOD ONCOL
[5]  
[Anonymous], INT J GYNAECOL OB S1
[6]  
[Anonymous], CHIN J CLIN
[7]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[8]   Plasma immune analytes in patients with epithelial ovarian cancer [J].
Block, Matthew S. ;
Maurer, Matthew J. ;
Goergen, Krista ;
Kalli, Kimberly R. ;
Erskine, Courtney L. ;
Behrens, Marshall D. ;
Oberg, Ann L. ;
Knutson, Keith L. .
CYTOKINE, 2015, 73 (01) :108-113
[9]   miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities [J].
Calura, Enrica ;
Fruscio, Robert ;
Paracchini, Lara ;
Bignotti, Eliana ;
Ravaggi, Antonella ;
Martini, Paolo ;
Sales, Gabriele ;
Beltrame, Luca ;
Clivio, Luca ;
Ceppi, Lorenzo ;
Di Marino, Mariacristina ;
Nerini, Ilaria Fuso ;
Zanotti, Laura ;
Cavalieri, Duccio ;
Cattoretti, Giorgio ;
Perego, Patrizia ;
Milani, Rodolfo ;
Katsaros, Dionyssios ;
Tognon, Germana ;
Sartori, Enrico ;
Pecorelli, Sergio ;
Mangioni, Costantino ;
D'Incalci, Maurizio ;
Romualdi, Chiara ;
Marchini, Sergio .
CLINICAL CANCER RESEARCH, 2013, 19 (15) :4114-4123
[10]   miR-335 Represents an Independent Prognostic Marker in Epithelial Ovarian Cancer [J].
Cao, Jin ;
Cai, Jing ;
Huang, Da ;
Han, Qing ;
Chen, Yanxia ;
Yang, Qiang ;
Yang, Chun ;
Kuang, Yan ;
Li, Donglin ;
Wang, Zehua .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 141 (03) :437-442